Personalis (NASDAQ:PSNL) Coverage Initiated at Craig Hallum

Analysts at Craig Hallum assumed coverage on shares of Personalis (NASDAQ:PSNL - Get Free Report) in a report released on Monday, MarketBeat.com reports. The brokerage set a "buy" rating and a $8.00 price target on the stock. Craig Hallum's price target indicates a potential upside of 124.72% from the company's current price.

A number of other research firms have also weighed in on PSNL. Lake Street Capital upped their target price on shares of Personalis from $7.00 to $9.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. HC Wainwright reissued a "buy" rating and issued a $8.00 price objective on shares of Personalis in a research note on Friday, February 28th. Finally, Needham & Company LLC dropped their target price on Personalis from $7.25 to $7.00 and set a "buy" rating on the stock in a report on Friday, February 28th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Personalis has an average rating of "Buy" and an average price target of $7.80.

Personalis Stock Down 1.4 %

NASDAQ:PSNL traded down $0.05 on Monday, hitting $3.56. The stock had a trading volume of 652,049 shares, compared to its average volume of 920,322. The company has a market cap of $314.22 million, a PE ratio of -2.12 and a beta of 1.73. Personalis has a 52 week low of $1.14 and a 52 week high of $7.20. The business's fifty day moving average is $4.79 and its 200 day moving average is $4.87.

Remove Ads

Personalis (NASDAQ:PSNL - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.23) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.09. Personalis had a negative net margin of 104.52% and a negative return on equity of 66.07%. The business had revenue of $16.80 million during the quarter, compared to the consensus estimate of $15.48 million. Equities analysts predict that Personalis will post -1.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Personalis

A number of institutional investors have recently added to or reduced their stakes in the company. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Personalis in the 4th quarter worth approximately $28,000. JPMorgan Chase & Co. boosted its position in Personalis by 2,827.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,854 shares of the company's stock worth $34,000 after purchasing an additional 5,654 shares during the last quarter. Olympiad Research LP bought a new position in Personalis in the 4th quarter valued at $59,000. Alpine Global Management LLC bought a new position in Personalis in the 4th quarter valued at $60,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Personalis during the 4th quarter valued at $63,000. 61.91% of the stock is owned by institutional investors.

Personalis Company Profile

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.